An Open-Label, Non-randomized, Prospective Biomarker Study to Assess Analytic Concordance Between Non-invasive Testing and Tissue Testing for EGFR T790M Mutation Detection in Patients With Non-small Cell Lung Cancer
Phase of Trial: Phase IV
Latest Information Update: 13 Dec 2018
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Diagnostic use
- Acronyms RADIANCE
- Sponsors AstraZeneca
- 05 Dec 2018 Status changed from active, no longer recruiting to completed.
- 01 Oct 2018 Planned End Date changed from 31 May 2021 to 30 Oct 2018.
- 01 Oct 2018 Planned primary completion date changed from 31 May 2021 to 30 Oct 2018.